Xin Yi Hua
StarMagnolia biondii Pamp.
Traditionally used for
- Headaches
- Nose & throat
Cautions & contraindications
- Allergy risk
☯ TCM Properties
Disperses Wind-Cold; Unblocks the Nasal Passages; Raises Clear Yang
Traditional Chinese Uses
Xin Yi Hua (magnolia flower bud) is a warm, pungent herb that opens the nasal passages, disperses Wind-Cold from the head, and clears Dampness from the sinuses. It is the primary herb in Chinese medicine for nasal congestion, rhinitis, sinusitis, and headache from Wind-Cold obstruction of the nasal passages and sinuses. Its targeted action on the nose makes it specific to nasal conditions in a way that few other herbs can match, and it appears in the majority of classical sinus and rhinitis formulas.
Western Herbalism Properties
Relationships
Full-screen graph →Click a node for details · double-click to expand it · Ctrl/⌘ + scroll or two fingers to zoom and pan.
Botanical Description
Magnolia biondii is a deciduous tree native to central China, reaching 10-12 meters in height with a rounded crown and smooth grey bark. The alternate leaves are elliptic to obovate, 10-18 cm long, with entire margins and short petioles. Conspicuously, the unopened flower buds form in late summer and persist through winter, covered in dense silvery-grey or brownish pubescence that gives them a fuzzy, conical appearance. In early spring before the leaves emerge, the buds open to reveal fragrant tepals that are white inside and pink or purple-flushed outside. The fruit is an aggregate of follicles. In TCM, the dried unopened flower buds (Xin Yi Hua) are used as a warm, acrid herb for nasal congestion and sinus disorders.
Active Constituents
Magnolin
Tetrahydrofurofuran (bisepoxy) lignanConcentration: the Chinese Pharmacopoeia requires Magnoliae Flos to contain not less than 0.4 percent magnolin; Magnolia biondii buds carry significantly more magnolin than Magnolia denudata or Magnolia liliiflora buds by HPLC
The assay marker for the drug and the reason Magnolia biondii is the preferred of the permitted species. Magnolin is an inhibitor of the MEK-ERK axis and, with the other tetrahydrofurofuranoid lignans, suppresses inflammatory signalling through NF-kappaB and MAPK and dampens allergic responses. Magnolin accumulation peaks in the buds in October, with the biosynthetic genes upregulated in August and September, so harvest timing determines potency.
Fargesin
Tetrahydrofurofuran (bisepoxy) lignanThe second principal lignan, found in every batch of Magnolia biondii examined alongside magnolin. It is anti-inflammatory, antioxidative, anti-melanogenic and anti-apoptotic. Pharmacokinetically it is the constituent to watch: its hepatic extraction ratio across five species is 0.59 to 0.78, indicating moderate to extensive hepatic metabolism, and its O-demethylenation to fargesin catechol is catalysed by CYP2C9, CYP3A4, CYP2C19 and CYP2C8, with O-desmethylfargesin formed by CYP2C9 and CYP2B6.
Aschantin
Tetrahydrofurofuran (bisepoxy) lignanOne of the seven major structurally similar tetrahydrofurofuranoid lignans of Magnoliae Flos, alongside magnolin, fargesin, lirioresinol B dimethyl ether, epimagnolin, eudesmin and kobusin. As a group these are the constituents credited with the anti-inflammatory and antiallergic actions of the drug.
Epimagnolin
Tetrahydrofurofuran (bisepoxy) lignanA close structural analogue of magnolin within the same lignan group, contributing to the inhibition of NF-kappaB and MAPK signalling attributed to the total lignan fraction.
Eudesmin
Tetrahydrofurofuran (bisepoxy) lignanAnother member of the group, with reported anti-tumour, anti-inflammatory and neuroprotective activity. Its in vitro half-life is 181 minutes in human hepatocytes and 132.9 minutes in mouse, with phase I metabolism dominated by O-demethylation of the dimethoxyphenyl rings.
Kobusin
Tetrahydrofurofuran (bisepoxy) lignanThe seventh of the major tetrahydrofurofuranoid lignans catalogued from the flower buds.
Furofuran and tetrahydrofuran lignans (33 isolated, including antiallergic members)
LignansA systematic isolation from Magnolia biondii yielded 33 lignans, four of them new, and showed that furofuran and tetrahydrofuran lignans are the main constituent class of the species. Five of the 33 significantly inhibited beta-hexosaminidase release from mouse bone marrow-derived mast cells, locating the antiallergic activity of the drug in this class and in suppression of mast cell activation rather than in the volatile oil.
1,8-Cineole (eucalyptol)
Bicyclic monoterpene etherConcentration: 14.50 percent of the volatile oil of Magnolia biondii flower buds, significantly higher than in Magnolia denudata or Magnolia sprengeri
The volatile marker that best separates Magnolia biondii from the other two Pharmacopoeia sources of Xin Yi. 1,8-Cineole is the constituent of the oil with the clearest relevance to nasal use, being a well-known secretolytic and anti-inflammatory airway agent in its own right. Volatile oil content tracks the density of oil cells in the bud and varies with growth stage.
Volatile oil monoterpenes (alpha-pinene, beta-pinene, sabinene, myrcene, camphor, terpinen-4-ol, alpha-terpineol)
Monoterpenes and monoterpenoidsThe aromatic fraction that gives the bud its pungent warming character and carries the antibacterial activity of the oil. This is the fraction exploited in the microemulsion and transnasal formulations developed to get around the poor water solubility and low bioavailability of the oil.
Naringenin
FlavanoneIdentified by UHPLC-Q-Exactive Orbitrap MS among 26 compounds in Magnolia biondii bud extracts and pinpointed by Connectivity Map and network analysis as a primary active constituent of the ethanol extract, which inhibited JAK1 and STAT1 phosphorylation and the proliferation and migration of A375 and B16F10 melanoma cells while sparing normal keratinocytes.
Sesquiterpenes (trans-caryophyllene, beta-ylangene, delta-cadinene, alpha-cubebol)
SesquiterpenesMinor volatile constituents of the bud oil. They contribute to the aroma profile that also makes the oil commercially useful as a perfumery and flavouring material, but they have no separately established therapeutic role in this drug.
⚠ Drug Interactions
xin-yi-hua (the duplicate record of this same drug in this corpus)
The slug xin-yi-hua-2 and the existing slug xin-yi-hua are the same drug: the dried unopened flower buds of Magnolia biondii Pamp., recorded once as Magnoliae Flos and once as Flos Magnoliae, which are the same Latin pharmacopoeial name written in two word orders. There is no pharmacological difference to research; the duplication is a data problem, not a botanical one.
Clinical note: Merge the two records. Xin Yi and Xin Yi Hua are the same drug, and no formula should list both.
CYP2C9, CYP3A4, CYP2C19 and CYP2C8 substrates (warfarin, phenytoin, glimepiride, midazolam, clopidogrel)
Fargesin, one of the two principal lignans of this drug, is extensively metabolised in the liver, with hepatic extraction ratios of 0.59 to 0.78 across human, dog, monkey, mouse and rat hepatocytes. Its O-demethylenation to fargesin catechol is catalysed by CYP2C9, CYP3A4, CYP2C19 and CYP2C8, and O-desmethylfargesin formation by CYP2C9 and CYP2B6, with subsequent COMT methylation and UGT and SULT conjugation. Eudesmin, another lignan of the group, is likewise CYP-dependent with moderate stability. Being a substrate of these enzymes creates the possibility of competition, but no inhibition constant, no clinical pharmacokinetic study and no case report exists for this herb, so the direction and size of any effect are unknown.
Clinical note: No action needed at ordinary doses. Keep it in mind only for a patient on a narrow-therapeutic-index CYP2C9 substrate such as warfarin or phenytoin who is taking a concentrated Xin Yi lignan extract rather than a decoction, and monitor the usual clinical endpoint if so.
PDE4 inhibitors (roflumilast, apremilast, crisaborole) and theophylline
Total lignans from the flower buds of Magnolia biondii were shown to inhibit PDE4 enzymatic activity directly in a scintillation proximity assay, in the course of demonstrating dual MEK1 and PDE4 targeting in a DNCB-induced mouse model of atopic dermatitis. Mechanistic overlap with a prescribed PDE4 inhibitor is therefore plausible. This is enzyme-level and mouse-level work with a total lignan fraction; no human exposure data exist and a decoction of the bud is a much weaker stimulus.
Clinical note: Not a reason to withhold the herb. Note it only if a patient on roflumilast or apremilast develops disproportionate nausea, diarrhoea or headache after starting a concentrated Xin Yi lignan product.
Magnolia denudata, Magnolia sprengeri and Magnolia liliiflora buds dispensed as Xin Yi
The Chinese Pharmacopoeia accepts the flower buds of Magnolia biondii, Magnolia denudata and Magnolia sprengeri equally as Xin Yi, and Magnolia liliiflora buds also circulate. A comparative study of the three official Hubei sources by anatomy, GC-MS and chemometrics found volatile oil content and composition differing between them, with 1,8-cineole varying significantly and Magnolia biondii the highest at 14.50 percent. Magnolin, the assay marker, is significantly higher in Magnolia biondii than in Magnolia denudata or Magnolia liliiflora. The species substitution is not a toxicity hazard, but it means a batch labelled only Xin Yi can be materially weaker than the one a prescription was written for.
Clinical note: If you are dosing on the strength of the Magnolia biondii literature, ask which species the material is. When a nasal or antiallergic effect is the objective, Magnolia biondii buds are the best-supported source. Reject material collected after the buds have opened; the drug is defined as the unopened bud gathered from late winter to early spring.
Antihistamines, intranasal corticosteroids and mast cell stabilisers
The antiallergic action of this drug is located in its lignans and works upstream of the histamine receptor: five of 33 isolated lignans significantly inhibited beta-hexosaminidase release from mouse bone marrow-derived mast cells, and the total lignan fraction suppressed FcepsilonRI-mediated degranulation and TNF-alpha and IL-6 secretion while reducing mast cell infiltration in vivo. Bisepoxylignans isolated by bioassay-guided fractionation showed the same effect. Because the mechanism is degranulation rather than receptor blockade, the overlap with an antihistamine is complementary rather than duplicative, and no adverse interaction has been reported.
Clinical note: Concurrent use is not a problem and is the ordinary clinical situation. Do not present the herb as a substitute for controller therapy in allergic rhinitis; the evidence is cell and mouse work, not trials.
Dosage
| Form | Amount | Frequency | Duration | Population | Notes |
|---|---|---|---|---|---|
| decoction (pre-decocted / bagged) | 3–10 g | Daily | — | — | 中国药典 2020 monograph 【辛夷】【用法与用量】3～10g,包煎。外用适量。 【性味与归经】辛，温。归肺、胃经。 — Matched by hand: Magnolia biondii is a ChP source species of 辛夷; 辛夷花 is the same drug under its colloquial name. Chinese Pharmacopoeia 2020, quoted verbatim. |
Evidence Tier
Moderate evidence · 6 studiesRecorded studies by study design, strongest design at the top. This is a study-design tier only, not a GRADE rating: it does not weigh risk of bias, consistency or precision.
Systematic review / meta-analysis
0
Randomized controlled trial
0
Other clinical trial
0
Observational / case report
0
In vitro / animal
6
1 verified · 5 unverified
Show 6 studies
- New furofuran and tetrahydrofuran lignans from the flower buds of Magnolia biondii Pamp and their antiallergic effects
- Bioassay-guided isolation of bisepoxylignans from the flower buds of Magnolia biondii Pamp and their antiallergic effects
- Dual targeting of MEK1 and PDE4 by Total lignans from flower buds of Magnolia biondii Pamp. Alleviates atopic dermatitis
- Comparative metabolism of fargesin in human, dog, monkey, mouse, and rat hepatocytes
- Phytochemical Characterization, Antioxidant Activity, and Anti-Melanoma Mechanism of Flower Buds of Magnolia biondii Pamp.
- Assessment of quality in volatile oil from three basic sources of Xinyi from Hubei by anatomy, GC-MS, and chemometric methods
Other / unclassified
0
Verified: design read from PubMed for a DOI that resolves to the cited paper Unverified: taken from the study's recorded description
Some DOIs on this page have not been checked against the registries yet; their studies count as unverified until they are.
Clinical Studies
New furofuran and tetrahydrofuran lignans from the flower buds of Magnolia biondii Pamp and their antiallergic effects
Thirty-three lignans were obtained from Magnolia biondii, including two new furofuran and two new tetrahydrofuran lignans and sixteen known ones isolated from the species for the first time. Tested on mouse bone marrow-derived mast cell degranulation, five of the compounds significantly inhibited beta-hexosaminidase release. The study establishes furofuran and tetrahydrofuran lignans as the main constituents of the species and ties the traditional use in allergic rhinitis and sinusitis to suppression of mast cell activation.
Bioassay-guided isolation of bisepoxylignans from the flower buds of Magnolia biondii Pamp and their antiallergic effects
Bioassay-guided fractionation of Magnolia biondii flower buds isolated bisepoxylignans and demonstrated antiallergic activity, the earlier work that directed attention to this lignan class as the antiallergic principle of the drug rather than the volatile oil.
Dual targeting of MEK1 and PDE4 by Total lignans from flower buds of Magnolia biondii Pamp. Alleviates atopic dermatitis
Total lignans from Magnolia biondii flower buds dose-dependently relieved atopic dermatitis-like disease in DNCB-treated mice, reducing epidermal hyperplasia and suppressing Il1b, Ccl5 and Ccl22. In vitro they inhibited FcepsilonRI-mediated mast cell degranulation and TNF-alpha and IL-6 secretion, and modulated macrophage function. Direct PDE4 enzyme inhibition was confirmed by scintillation proximity assay and MEK1 was identified as a direct target by docking and DARTS.
Comparative metabolism of fargesin in human, dog, monkey, mouse, and rat hepatocytes
Fargesin's hepatic extraction ratio across five species was 0.59 to 0.78, indicating moderate to extensive hepatic metabolism. Three phase I metabolites, fargesin catechol and two O-desmethylfargesins, and eleven phase II metabolites were characterised. Fargesin catechol formation by O-demethylenation is catalysed by CYP2C9, CYP3A4, CYP2C19 and CYP2C8; O-desmethylfargesin formation by CYP2C9 and CYP2B6; downstream conjugation involves COMT, UGT and SULT. This is the pharmacokinetic basis for any CYP-mediated interaction concern with this drug.
Phytochemical Characterization, Antioxidant Activity, and Anti-Melanoma Mechanism of Flower Buds of Magnolia biondii Pamp.
UHPLC-Q-Exactive Orbitrap MS identified 26 bioactive compounds in Magnolia biondii bud extracts. The ethanol extract was high in total flavonoids and polyphenols with corresponding DPPH and ABTS antioxidant activity. Network pharmacology pointed to JAK/STAT signalling with STAT3 and STAT1 as core targets, and western blotting confirmed inhibition of JAK1 and STAT1 phosphorylation. The extract and naringenin, identified as a primary active constituent, inhibited proliferation and migration of A375 and B16F10 melanoma cells with relatively low toxicity to normal keratinocytes. Cell-culture work only.
Assessment of quality in volatile oil from three basic sources of Xinyi from Hubei by anatomy, GC-MS, and chemometric methods
GC-MS and microscopy compared the volatile oil of the flower buds of the three Pharmacopoeia sources of Xinyi, Magnolia biondii, Magnolia denudata and Magnolia sprengeri, across growth stages. Volatile oil content differed between species and correlated positively with oil cell density, and 1,8-cineole varied significantly between them, reaching 14.50 percent in Magnolia biondii. The practical message is that the three permitted species are not interchangeable on chemistry.
Historical Texts
Shen Nong Ben Cao Jing
Han dynasty, c. 200 CEBen Cao Gang Mu
Ming dynasty, 1596 CEReferences
- Xu L, Sun L, Chen Y, Nie T, Zhu H, Yin Z. Magnolia biondii Pamp.: A comprehensive review of the pharmacognosy, phytochemistry, pharmacology, and applications . Industrial Crops and Products (2024) [DOI]
- Yi X, Xiao Z, Chen J, Chen G, Ma P. Pharmacological Potential and Molecular Targets of Tetrahydrofurofuranoid Lignans From Magnoliae Flos . Drug Design, Development and Therapy (2025) [DOI]
- Guo Q, Wang X, Wang Y, Zhou P, Zhang X. Volatile Oil of Magnolia biondii Pamp. for Transnasal Administration: Its Preparation, Characterization, and Mechanism of Action in the Treatment of Allergic Rhinitis . Current Pharmaceutical Biotechnology (2024) [DOI]
This information is for educational purposes only and is not intended to replace professional medical advice. Always consult a qualified healthcare provider before using any herbal remedy, especially if you are pregnant, nursing, or taking medications.
📝 Notes
Public notes from the community and your own private notes on Xin Yi Hua.
No notes yet.